Role of the Circulating Exerkine GPLD1 in Ameliorating Alzheimer’s Disease Pathology

2022, 2024

The research described in this proposal will investigate the beneficial effect of the exercise-induced, liver-derived blood factor Glycosylphosphatidylinositol-Specific Phospholipase D1 (GPLD1) on the brain vasculature as a critical mediator in combating drivers of Alzheimer’s disease. This study will delineate cellular and molecular mechanisms underlying the benefits of systemic GPLD1 in restoring cognitive function and ameliorating Alzheimer’s disease pathology in the hippocampus. The results from this study will have significant translational potential, positing GPLD1 as a novel therapeutic target to reverse functional impairments in Alzheimer’s disease.

Funding to Date



Studies of Alternative Neurodegenerative Pathways, Translational


Saul Villeda, B.S., Ph.D.